Do pre-procedural serum GDF11 levels predict the progression of ischemic mitral regurgitation and heart failure risk in STEMI patients after pPCI?
Serum GDF11 serves as a prognostic biomarker in STEMI patients undergoing pPCI, where lower levels independently predict the exacerbation of ischemic mitral regurgitation and increased risk of post-procedural heart failure.
Ischemic mitral regurgitation (IMR) commonly complicates pPCI in STEMI patients. GDF11, a protective cardiovascular factor, may influence IMR progression and prognosis. Among 310 STEMI patients, 126 with recent normal echocardiography underwent pPCI with pre-procedural GDF11 testing. Cox regression, ROC analysis, and Spearman's correlation assessed GDF11's predictive value for IMR exacerbation and cardiac function. Lower GDF11 predicted IMR worsening (HR = 0.982, P = 0.004; AUC = 0.744, P < 0.001). High GDF11 patients had reduced IMR progression (P = 0.0013) and heart failure risk (P = 0.0003). GDF11 correlated with LVEF and left atrial changes (P < 0.05). Serum GDF11 independently predicts IMR exacerbation and post-pPCI heart failure, serving as a prognostic biomarker in STEMI.
Ye et al. (Thu,) studied this question.